Medicinal Mishap: Death from diltiazem-ibrutinib interaction
Authors:
- Nazanin FalconerNFNazanin Falconer
- Marissa RyanMRMarissa Ryan
- Belinda BadmanBBBelinda Badman
- Christine CarringtonCCChristine Carrington
Open Access
- 1 June 2021
- journal article
- editorial
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 44 (3) , 107-108
Abstract
Beware of interactions with tyrosine kinase inhibitors.Keywords
This publication has 3 references indexed in Scilit:
- Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular riskWiener klinische Wochenschrift, 2019
- IbrutinibAustralian Prescriber, 2015
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signalingBlood, 2014